EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-Dose Toxicity Study of Self-Assembling A6K/Sodium Borocaptate (BSH) Peptide Nanotubes as a New Boron Delivery Agent for Boron Neutron Capture Therapy (BNCT) in Mice

Miharu Kano iD, Katsuaki Ieguchi iD, Tomonari Kasai, Kazuki Tsuchida, Yosuke Sasaki iD, Eisuke Shiozawa iD, Kouzou Murakami, Yasuaki Ichikawa, Satoshi Wada iD, Naoki Hayashi, Toshiko Yamochi

Cancers · 27.04.2026 · 18 (9) · 1382

DOI: 10.3390/cancers18091382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 27.04.2026. Verfasst von Miharu Kano und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Science and Technology Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Boron neutron capture therapy (BNCT) is a type of targeted radiotherapy with considerable therapeutic potential that may be combined with immune checkpoint inhibitors (ICIs) to enhance systemic antitumor immunity. Its efficacy relies on the efficient and safe delivery of boron to cancer cells. This study evaluated the acute toxicity of a self-assembling peptide-based boron carrier composed of A6K and sodium borocaptate (BSH) at a 1:10 molar ratio (A6K/BSH boron drug), which had previously shown excellent tumor-selective accumulation and prolonged intracellular retention.

Methods

A single-dose intraperitoneal toxicity study was performed in 6-week-old BALB/c mice (n = 6 per group; 3 males and 3 females). Animals received BSH-equivalent doses of 0, 30, 100, 300, or 600 mg/kg and were observed for 14 days. Mortality, clinical signs, body weight, gross necropsy findings, and histopathological characteristics of major organs were then assessed.

Results

No mortality or treatment-related clinical signs were observed. Body weight changes were comparable between the control and treated groups. Gross necropsy revealed no treatment-related abnormalities. Histopathology showed mild hepatocellular hypertrophy and granular degeneration without dose dependency. No other organ toxicities or sex-related differences were detected.

Conclusions

A single intraperitoneal administration of the A6K/BSH boron drug up to 600 mg/kg (BSH-equivalent) produced no evident acute systemic toxicity, suggesting that the approximate lethal dose exceeds 600 mg/kg for both sexes. This initial safety assessment supports the further development of the A6K/BSH boron drug as a boron delivery agent for BNCT. Further studies are needed to confirm its safety under clinically relevant conditions.

Schlagwörter

Stichwörter der Autor:innen

acute toxicityboron deliveryboron neutron capture therapypreclinical studytoxicity study

Autor:innen und Institutionen

  • Department of Pathology, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
  • Division of Breast Surgical Oncology, Department of Surgery, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
  • Center for Electron Microscopy, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
  • Energy System Engineering Research Group, Department of Applied Energy, Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8603, Japan.
  • Division of Radiology, Department of Radiology, School of Medicine, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.
  • Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology and Therapeutics, Showa Medical University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8555, Japan.

ORCID-Profile: Miharu Kano, Katsuaki Ieguchi, Yosuke Sasaki, Eisuke Shiozawa, Satoshi Wada

Förderung

  • Japan Science and Technology Agency

Zitieren

APA

Kano, M., Ieguchi, K., Kasai, T., Tsuchida, K., Sasaki, Y., Shiozawa, E., Murakami, K., Ichikawa, Y., Wada, S., Hayashi, N., & Yamochi, T. (2026). Single-Dose Toxicity Study of Self-Assembling A6K/Sodium Borocaptate (BSH) Peptide Nanotubes as a New Boron Delivery Agent for Boron Neutron Capture Therapy (BNCT) in Mice. Cancers, 18(9), 1382. https://doi.org/10.3390/cancers18091382

Vancouver

Kano M, Ieguchi K, Kasai T, Tsuchida K, Sasaki Y, Shiozawa E, et al. Single-Dose Toxicity Study of Self-Assembling A6K/Sodium Borocaptate (BSH) Peptide Nanotubes as a New Boron Delivery Agent for Boron Neutron Capture Therapy (BNCT) in Mice. Cancers. 2026;18(9):1382. doi:10.3390/cancers18091382

BibTeX
@article{Kano2026,
  author = {Kano, Miharu and Ieguchi, Katsuaki and Kasai, Tomonari and Tsuchida, Kazuki and Sasaki, Yosuke and Shiozawa, Eisuke and Murakami, Kouzou and Ichikawa, Yasuaki and Wada, Satoshi and Hayashi, Naoki and Yamochi, Toshiko},
  title = {Single-Dose Toxicity Study of Self-Assembling A6K/Sodium Borocaptate (BSH) Peptide Nanotubes as a New Boron Delivery Agent for Boron Neutron Capture Therapy (BNCT) in Mice},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1382},
  doi = {10.3390/cancers18091382}
}
Kostenlos starten →